Construction of acquired weakness risk prediction model in intensive care unit

doi:10.11958/20231011

Abstract

Abstract:

Objective To construct a risk prediction model for intensive care unit-acquired weakness (ICU-AW) to guide clinical prevention and treatment strategies. Methods The correlation between gender, age, age-adjusted Charlson Comorbidity Index (aCCI), injecting albumin, heart failure, rehabilitation treatment, midazolam dosage, norepinephrine dosage and mechanical ventilation duration in 1 063 patients admitted to the intensive care unit was analyzed. Independent risk factors were identified to establish the prediction model, and the predictive ability of the model was analyzed. Results Among 1 063 patients, 370 developed ICU-AW. Logistic regression analysis identified advanced age, higher aCCI, prolonged mechanical ventilation duration, increased midazolam and norepinephrine dosages, and heart failure as independent risk factors for ICU-AW, while rehabilitation treatment and injecting albumin were identified as independent protective factors. The regression equation of the prediction model was: Logit (P) = 0.017 × age + 0.008 × mechanical ventilation duration + 0.006 × norepinephrine dosage - 0.832 × rehabilitation treatment - 0.648 × injecting albumin + 1.224 × aCCI + 0.017 × midazolam dosage + 1.834 × heart failure - 6.806. The area under the curve (AUC) of the model was 0.908 (0.890-0.925), with the sensitivity of 82.20% and specificity of 82.40%. Conclusion The model constructed using these variables demonstrates good predictive efficiency and can provide new insights for clinical prevention and treatment of ICU-AW.

Key words: intensive care unit-acquired weakness, clinical prevention and treatment, independent risk factors, predictive model

CLC Number:

R597

Figures/Tables 4

References 20

[1]	TAYLOR C. Intensive care unit acquired weakness[J]. Anaesth Intensive Care Med, 2021, 22(2):81-84. doi:10.1016/j.mpaic.2020.12.006.
[2]	RAURELL-TORREDÀ M, ARIAS-RIVERA S, MARTÍ J D, et al. Care and treatments related to intensive care unit-acquired muscle weakness:a cohort study[J]. Aust Crit Care, 2021, 34(5):435-445. doi:10.1016/j.aucc.2020.12.005.
[3]	VANHOREBEEK I, LATRONICO N, VAN DEN BERGHE G. ICU-acquired weaknes[J]. Intensive Care Med, 2020, 46(4):637-653. doi:10.1007/s00134-020-05944-4.
[4]	PANAHI A, MALEKMOHAMMAD M, SOLEYMANI F, et al. The prevalence and outcome of intensive care unit acquired weakness[J]. Tanaffos, 2020, 19(3):250-255.
[5]	ROUSSEAU A F, PRESCOTT H C, BRETT S J, et al. Long-term outcomes after critical illness:recent insights[J]. Crit Care, 2021, 25(1):108. doi:10.1186/s13054-021-03535-3.
[6]	JIANG T, LIN T, SHU X, et al. Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation:a systematic review and meta-analysis[J]. Crit Care, 2022, 26(1):140. doi:10.1186/s13054-022-04015-y.
[7]	BIRCH T B. Neuromuscular disorders in the intensive care unit[J]. Continuum, 2021, 27(5):1344-1364. doi:10.1212/CON.0000000000001004.
[8]	吴雨晨, 王国强, 丁楠楠, 等. 国内外ICU获得性衰弱研究现状的可视化分析[J]. 中华现代护理杂志, 2019, 25(25):3199-3205.
	WU Y C, WANG G Q, DING N N, et al. Visualization study on research status of intensive care unit-acquired weakness in China and abroad[J]. Chin J Mod Nurs, 2019, 25(25):3199-3205. doi:10.3760/cma.j.issn.1674-2907.2019.25.008.
[9]	CHARLSON M E, POMPEI P, ALES K L, et al. A new method of classifying prognostic comorbidity in longitudinal studies:development and validation[J]. J Chronic Dis, 1987, 40(5):373-83. doi:10.1016/0021-9681(87)90171-8.
[10]	BOELENS Y F N, MELCHERS M, VAN ZANTEN A R H. Poor physical recovery after critical illness:incidence,features,risk factors,pathophysiology,and evidence-based therapies[J]. Curr Opin Crit Care, 2022, 28(4):409-416. doi:10.1097/MCC.0000000000000955.
[11]	LI Z, ZHANG Q, ZHANG P, et al. Prevalence and risk factors for intensive care unit acquired weakness:a protocol for a systematic review and meta-analysis[J]. Medicine, 2020, 99(36):e22013. doi:10.1097/MD.0000000000022013.
[12]	YANG Z, WANG X, WANG F, et al. A systematic review and meta-analysis of risk factors for intensive care unit acquired weakness[J]. Medicine (Baltimore), 2022, 101(43):e31405. doi:10.1097/MD.0000000000031405.
[13]	郭彦, 徐礼娟. ICU获得性衰弱危险因素的Meta分析[J]. 循证护理, 2022, 8(16):2136-2141.
	GUO Y, XU L J. Risk factors of intensive care unit-acquired weakness:a Meta-analysis[J]. Chin Evid Based Nurs, 2022, 8(16):2136-2141. doi:10.12102/j.issn.2095-8668.2022.16.002.
[14]	刘杨, 罗健, 刘苗, 等. 基于Meta分析构建ICU获得性衰弱风险预测模型[J]. 护理学杂志, 2022, 37(7):29-33.
	LIU Y, LUO J, LIU M, et al. Construction of a risk prediction model for ICU acquired weakness-based on Meta-analysis[J]. J Nurs Sci, 2022, 37(7):29-33. doi:10.3870/j.issn.1001-4152.2022.07.029.
[15]	CHEN J, HUANG M. Intensive care unit-acquired weakness:recent insights[J]. J Intensive Med, 2023. doi:10.1016/j.jointm.2023.07.002.
[16]	WANG W, XU C, MA X, et al. Intensive care unit-acquired weakness:a review of recent progress with a look toward the future[J]. Front Med (Lausanne), 2020, 7:559789. doi:10.3389/fmed.2020.559789.
[17]	WOLFE K S, PATEL B K, MACKENZIE E L, et al. Impact of vasoactive medications on icu-acquired weakness in mechanically ventilated patients[J]. Chest, 2018, 154(4):781-787. doi:10.1016/j.chest.2018.07.016.
[18]	MENDELSON A A, ERICKSON D, VILLAR R. The role of the microcirculation and integrative cardiovascular physiology in the pathogenesis of ICU-acquired weakness[J]. Front Physiol, 2023, 14:1170429. doi:10.3389/fphys.2023.1170429.
[19]	ZHOU W, YU L, FAN Y, et al. Effect of early mobilization combined with early nutrition on acquired weakness in critically ill patients (EMAS):a dual-center,randomized controlled trial[J]. PLoS One, 2022, 17(5):e0268599. doi:10.1371/journal.pone.0268599.
[20]	WANG L, ZHANG Z. Progress in rehabilitation treatments for sepsis patients in ICU[J]. J Hum Health Res, 2022, 1(4):1-8. doi:10.14302/issn.2576-9383.jhhr-22-4146.

组别	n	性别（男/女）	年龄/岁	aCCI/分	输注白蛋白	咪达唑仑用量/mg	去甲肾上腺素用量/mg	机械通气时间/h	康复治疗	心力衰竭
非ICU-AW组	693	385/308	58.58±18.75	4.28±1.31	461（66.52）	0（0，20）	0（0，16）	0（0，21.0）	370（5.34）	250（36.06）
ICU-AW组	370	252/118	68.29±18.72	5.90±1.52	330（88.92）	50（0，370）	20（0，120）	107.5（9.0，247.5）	92（24.86）	157（42.43）
χ²、t或Z		16.062^＊	3.932^＊	5.101^＊	66.930^＊	2.873^＊	2.079^＊	10.106^＊	81.960^＊	17.503^＊

组别	n	性别（男/女）	年龄/岁	aCCI/分	输注白蛋白	咪达唑仑用量/mg	去甲肾上腺素用量/mg	机械通气时间/h	康复治疗	心力衰竭
非ICU-AW组	693	385/308	58.58±18.75	4.28±1.31	461（66.52）	0（0，20）	0（0，16）	0（0，21.0）	370（5.34）	250（36.06）
ICU-AW组	370	252/118	68.29±18.72	5.90±1.52	330（88.92）	50（0，370）	20（0，120）	107.5（9.0，247.5）	92（24.86）	157（42.43）
χ²、t或Z		16.062^＊	3.932^＊	5.101^＊	66.930^＊	2.873^＊	2.079^＊	10.106^＊	81.960^＊	17.503^＊

参数	β	SE	Wald χ²	P	OR	OR95%CI
性别	-0.134	0.190	0.493	0.482	0.875	0.602~1.271
年龄	0.017	0.006	7.675	0.006	1.017	1.005~1.028
aCCI	1.224	0.099	152.033	0.001	3.402	2.801~4.133
输注白蛋白	-0.648	0.198	10.682	0.013	0.523	0.354~0.771
咪达唑仑用量	0.017	0.005	14.006	<0.001	1.018	1.008~1.027
去甲肾上腺素用量	0.006	0.002	8.492	0.002	1.006	1.002~1.010
机械通气时间	0.008	0.001	30.710	<0.001	1.008	1.005~1.010
康复治疗	-0.832	0.333	6.225	0.004	0.435	0.226~0.837
心力衰竭	1.834	0.279	43.306	<0.001	6.258	3.624~10.806
常数项	-6.806	0.743	83.984	<0.001	0.001

参数	β	SE	Wald χ²	P	OR	OR95%CI
性别	-0.134	0.190	0.493	0.482	0.875	0.602~1.271
年龄	0.017	0.006	7.675	0.006	1.017	1.005~1.028
aCCI	1.224	0.099	152.033	0.001	3.402	2.801~4.133
输注白蛋白	-0.648	0.198	10.682	0.013	0.523	0.354~0.771
咪达唑仑用量	0.017	0.005	14.006	<0.001	1.018	1.008~1.027
去甲肾上腺素用量	0.006	0.002	8.492	0.002	1.006	1.002~1.010
机械通气时间	0.008	0.001	30.710	<0.001	1.008	1.005~1.010
康复治疗	-0.832	0.333	6.225	0.004	0.435	0.226~0.837
心力衰竭	1.834	0.279	43.306	<0.001	6.258	3.624~10.806
常数项	-6.806	0.743	83.984	<0.001	0.001

指标	AUC	95%CI	截断值	敏感度/%	特异度/%	阳性预测值/%	阴性预测值/%	约登指数
模型	0.908	0.890~0.925	0.32	82.20	82.40	81.53	83.78	0.646
年龄	0.606	0.571~0.642	70.50岁	45.70	69.80	55.40	70.23	0.155
aCCI	0.789	0.763~0.816	4.5分	76.20	65.10	53.82	83.17	0.413
输注白蛋白	0.612	0.578~0.646	是	74.30	45.30	42.05	76.77	0.196
咪达唑仑用量	0.645	0.607~0.682	155.00 mg	38.60	81.20	70.10	73.57	0.198
去甲肾上腺素用量	0.608	0.572~0.643	17.00 mg	25.90	76.90	65.21	82.37	0.228
机械通气时间	0.781	0.748~0.814	52.50 h	67.30	78.00	75.00	83.44	0.453
康复治疗	0.598	0.560~0.635	是	24.90	80.70	71.32	70.23	0.056
心力衰竭	0.564	0.528~0.601	是	42.40	70.40	43.37	69.61	0.128